S-1 induced hepatic steatosis in patients with pancreatic cancer: Retrospective analysis

Table 1 Demographic and clinical characteristics of patients with pancreatic cancer receiving S-1 treatment

	Number of patients (n = 22)
Age (yr), median (range)	68 (48-85)
Sex
Male	9
Female	13
Body mass index (kg/m2) median (range)	21 (18-27)
ECOG PS
0	15
1	5
2	2
Drinking habit
Yes	6
No	16
Diabetes mellitus
Yes	6
No	16
Disease status
Locally advanced	14
Metastatic	8
Liver metastasis
Yes	5
No	17
Biliary drainage
Yes	7
No	15
Combination with radiotherapy
Yes	12
No	10
Alanine transaminase concentration (U/L), median (range)	21 (8-73)

Table 2 Demographic and clinical characteristics of pancreatic cancer patients

	Without hepatic steatosis (n = 11)	With hepatic steatosis (n = 5)	P value
Age (yr), median (range)	70 (57-85)	67 (48-78)	0.39
Sex
Male	7	2	1
Female	10	3
Body mass index (kg/m2), median (range)	21.5 (17.9-26.9)	22.6 (19.0-25.3)	0.75
ECOG PS
0	11	4	1
1	4	1
2	2	0
Drinking habit
Yes	5	1	1
No	12	4
Diabetes mellitus
Yes	5	1	1
No	12	4
Disease status
Locally advanced	10	4	0.61
Metastatic	7	1
Liver metastasis
Yes	5	0	0.29
No	12	5
Biliary drainage
Yes	4	3	0.27
No	13	2
Combination with radiotherapy
Yes	9	3	1
No	8	2
Alanine transaminase concentration (U/L), median (range)	24 (8-57)	20.5 (11-73)	0.97